Prevalence of DNA of fourteen human polyomaviruses determined in blood donors.
Journal
Transfusion
ISSN: 1537-2995
Titre abrégé: Transfusion
Pays: United States
ID NLM: 0417360
Informations de publication
Date de publication:
12 2019
12 2019
Historique:
received:
20
05
2019
revised:
24
09
2019
accepted:
24
09
2019
pubmed:
22
10
2019
medline:
17
6
2020
entrez:
22
10
2019
Statut:
ppublish
Résumé
Human polyomaviruses (HPyVs), like herpesviruses, cause persistent infection in a large part of the population. In immunocompromised and elderly patients, PyVs cause severe diseases such as nephropathy (BK polyomavirus [BKPyV]), progressive multifocal leukoencephalopathy (JC polyomavirus [JCPyV]), and skin cancer (Merkel cell polyomavirus [MCPyV]). Like cytomegalovirus, donor-derived PyV can cause disease in kidney transplant recipients. Possibly blood components transmit PyVs as well. To study this possibility, as a first step we determined the presence of PyV DNA in Dutch blood donations. Blood donor serum samples (n = 1016) were analyzed for the presence of DNA of 14 HPyVs using HPyV species-specific quantitative polymerase chain reaction (PCR) procedures. PCR-positive samples were subjected to confirmation by sequencing. Individual PCR findings were compared with the previously reported PyV serostatus. MC polyomavirus DNA was detected in 39 donors (3.8%), JCPyV and TS polyomavirus (TSPyV) DNA in five donors (both 0.5%), and HPyV9 DNA in four donors (0.4%). BKPyV, WU polyomavirus (WUPyV), HPyV6, MW polyomavirus (MWPyV), and LI polyomavirus (LIPyV) DNA was detected in one or two donors. Amplicon sequencing confirmed the expected product for BKPyV, JCPyV, WUPyV, MCPyV, HPyV6, TSPyV, MWPyV, HPyV9, and LIPyV. For JCPyV a significant association was observed between detection of viral DNA and the level of specific IgG antibodies. In 5.4% of Dutch blood donors PyV DNA was detected, including DNA from pathogenic PyVs such as JCPyV. As a next step, the infectivity of PyV in donor blood and transmission via blood components to immunocompromised recipients should be investigated.
Sections du résumé
BACKGROUND
Human polyomaviruses (HPyVs), like herpesviruses, cause persistent infection in a large part of the population. In immunocompromised and elderly patients, PyVs cause severe diseases such as nephropathy (BK polyomavirus [BKPyV]), progressive multifocal leukoencephalopathy (JC polyomavirus [JCPyV]), and skin cancer (Merkel cell polyomavirus [MCPyV]). Like cytomegalovirus, donor-derived PyV can cause disease in kidney transplant recipients. Possibly blood components transmit PyVs as well. To study this possibility, as a first step we determined the presence of PyV DNA in Dutch blood donations.
STUDY DESIGN AND METHODS
Blood donor serum samples (n = 1016) were analyzed for the presence of DNA of 14 HPyVs using HPyV species-specific quantitative polymerase chain reaction (PCR) procedures. PCR-positive samples were subjected to confirmation by sequencing. Individual PCR findings were compared with the previously reported PyV serostatus.
RESULTS
MC polyomavirus DNA was detected in 39 donors (3.8%), JCPyV and TS polyomavirus (TSPyV) DNA in five donors (both 0.5%), and HPyV9 DNA in four donors (0.4%). BKPyV, WU polyomavirus (WUPyV), HPyV6, MW polyomavirus (MWPyV), and LI polyomavirus (LIPyV) DNA was detected in one or two donors. Amplicon sequencing confirmed the expected product for BKPyV, JCPyV, WUPyV, MCPyV, HPyV6, TSPyV, MWPyV, HPyV9, and LIPyV. For JCPyV a significant association was observed between detection of viral DNA and the level of specific IgG antibodies.
CONCLUSION
In 5.4% of Dutch blood donors PyV DNA was detected, including DNA from pathogenic PyVs such as JCPyV. As a next step, the infectivity of PyV in donor blood and transmission via blood components to immunocompromised recipients should be investigated.
Identifiants
pubmed: 31633816
doi: 10.1111/trf.15557
pmc: PMC6916541
doi:
Substances chimiques
DNA, Viral
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
3689-3697Informations de copyright
© 2019 The Authors. Transfusion published by Wiley Periodicals, Inc. on behalf of AABB.
Références
J Virol. 2012 Oct;86(19):10321-6
pubmed: 22740408
J Clin Virol. 2011 Sep;52(1):28-32
pubmed: 21705268
J Infect Dis. 2014 Nov 15;210(10):1595-9
pubmed: 24795478
PLoS Pathog. 2017 Mar 22;13(3):e1006292
pubmed: 28328962
Emerg Infect Dis. 2014 Jun;20(6):991-9
pubmed: 24866095
Am J Transplant. 2005 Sep;5(9):2213-21
pubmed: 16095500
PLoS Pathog. 2009 Mar;5(3):e1000363
pubmed: 19325891
J Infect Dis. 2003 May 15;187(10):1571-80
pubmed: 12721937
PLoS One. 2018 Oct 23;13(10):e0206273
pubmed: 30352098
Front Oncol. 2017 Nov 29;7:294
pubmed: 29238698
JAMA Neurol. 2017 Apr 1;74(4):437-444
pubmed: 28241186
J Clin Microbiol. 2018 Mar 26;56(4):
pubmed: 29305551
BMC Infect Dis. 2012 Dec 28;12:383
pubmed: 23270528
Blood. 2011 Jun 30;117(26):7099-101
pubmed: 21464370
J Clin Virol. 2017 May;90:46-51
pubmed: 28355579
Virology. 2017 Jun;506:45-54
pubmed: 28342387
J Clin Virol. 2009 Jul;45(3):249-54
pubmed: 19515607
PLoS One. 2013 Nov 21;8(11):e81078
pubmed: 24278381
Rev Med Virol. 2016 Mar;26(2):102-14
pubmed: 26663440
J Clin Virol. 2010 Feb;47(2):156-60
pubmed: 20042367
J Infect Dis. 2017 Apr 1;215(7):1080-1084
pubmed: 27578847
PLoS Pathog. 2010 Jul 29;6(7):e1001024
pubmed: 20686659
J Infect Dis. 2009 Mar 15;199(6):837-46
pubmed: 19434930
Vox Sang. 2018 Jul 18;:
pubmed: 30022500
Science. 2008 Feb 22;319(5866):1096-100
pubmed: 18202256
Emerg Infect Dis. 2010 Sep;16(9):1482-5
pubmed: 20735940
BMC Infect Dis. 2017 Jun 8;17(1):409
pubmed: 28595595
J Virol. 2007 Apr;81(8):4130-6
pubmed: 17287263
J Virol. 2012 Oct;86(19):10887
pubmed: 22966183
Emerg Infect Dis. 2011 Aug;17(8):1364-70
pubmed: 21801611
Infect Genet Evol. 2017 Oct;54:18-38
pubmed: 28634106
Transfusion. 2017 Jul;57(7):1787-1800
pubmed: 28497550
J Virol. 2011 May;85(9):4586-90
pubmed: 21307194
Emerg Infect Dis. 2009 Mar;15(3):489-91
pubmed: 19239773
Am J Transplant. 2017 Jan;17(1):161-172
pubmed: 27251361
Am J Epidemiol. 2016 Jan 1;183(1):61-9
pubmed: 26667254
Emerg Infect Dis. 2009 Sep;15(9):1496-8
pubmed: 19788824
Lancet Infect Dis. 2003 Oct;3(10):611-23
pubmed: 14522260
Virology. 2013 Feb 20;436(2):295-303
pubmed: 23276405
J Gen Virol. 2000 Aug;81(Pt 8):1967-73
pubmed: 10900035
J Virol Methods. 2006 Jul;135(1):32-42
pubmed: 16527364
Methods. 2001 Dec;25(4):419-29
pubmed: 11846611
J Am Acad Dermatol. 2017 May;76(5):932-940.e3
pubmed: 28040372
Cell Host Microbe. 2010 Jun 25;7(6):509-15
pubmed: 20542254
PLoS One. 2013;8(3):e58021
pubmed: 23516426
J Gen Virol. 2017 Dec;98(12):3060-3067
pubmed: 29095685
JAMA Neurol. 2014 May;71(5):596-602
pubmed: 24664166
J Clin Virol. 2016 Sep;82:101-107
pubmed: 27472520
Emerg Infect Dis. 2015 Feb;21(2):365-7
pubmed: 25626138
Clin Infect Dis. 2018 Jun 18;67(1):65-72
pubmed: 29346632
Front Microbiol. 2018 Aug 14;9:1806
pubmed: 30154763
PLoS Pathog. 2007 May 4;3(5):e64
pubmed: 17480120
Annu Rev Med. 2010;61:35-47
pubmed: 19719397
J Med Virol. 2013 Aug;85(8):1444-6
pubmed: 23723088
J Infect Dis. 2015 May 1;211(9):1437-46
pubmed: 25387582